Tuesday, March 31, 2009

Spaltudaq Becomes Theraclone Sciences

Seattle-based Spaltudaq, a developer of human antibodies for the treatment of influenza, HIV, and human cytomegalovirus, said Monday that the firm has changed its name to Theraclone Sciences. The firm said the new name "highlights our ability to clone and express clinically relevant, naturally fully human antibodies for clinical and commercial benefit." The company is backed by ARCH Venture Partners, Canaan Partners and Healthcare Ventures. The announcement came as it announced that it has identified two new antibodies that may neutralize HIV.